FY2018 Results Presentation Mar arch 2019 2019 Agenda: IDH - PowerPoint PPT Presentation

FY2018 Results Presentation Mar arch 2019 2019

Agenda: • IDH Today • FY2018 Results • Future Growth Today’s Presenters Dr Dr. . Hend El El She Sherbini Omar Bedewy Sherif El She El Gha hamrawi Chi hief Ex Exec ecutive Chi hief Fin Financial al Investor Rela elations s Offic ficer Offic ficer Dir Director 2 INTEGRATED DIAGNOSTICS HOLDINGS

IDH Today 3 INTEGRATED DIAGNOSTICS HOLDINGS

Who We Are Integrated Diagnostics Holding is a leading, fully-integrated provider of high-quality medical diagnostic services with a footprint spanning Egypt, Jordan, Sudan and Nigeria Our Services Our Patients Immunology Ra Radiology Hematology Wal alk-In Patients Endocrinology Clinical Chem hemist stry Mol olecular Biology IDH’s walk-in in clients, s, also so referred to to as as “self - payers”, represe sented 41 41% of of th the Group’s revenues, and include individuals who pay out of of pocket in in CytogenEtics Hato topathology Microbiology adv dvance of of test sts be being completed. Our Brands Accreditations Contract Patients IDH’s contract clients, ts, who in in 2018 2018 represe sented 59 59% of of th the Group’s revenues, s, include insti titu tuti tions su such as as unions, s, sy syndicate tes, private te and public insu surance companies, banks and corporations who enter into to one year renewable con ontr tracts at at agreed rate tes pe per-test st and nd on on a pe per-client basi basis. + 30 30 years 6 key brands 6 423 423 28.8 MN Track record With strong awareness Branch labs as at FY18 FY18 Tests EGP 1.9 .9 BN +1,400 4 7.0 .0 MN FY18 Revenues Diagnostic tests offered Country footprint (Egypt, FY18 Patients Jordan, Sudan & Nigeria) 4 INTEGRATED DIAGNOSTICS HOLDINGS

Our Geography IDH’s branch network of 423 labs at FY2018 spans 4 countries, the largest of which is Egypt 19 The Company ’ s Egyptian operations contributed 84% of consolidated Revenues in FY2018 branches 371 Jordan EGYPT Branches 84.0% 1979 Egypt FY2018 Cair airo Regio ion 44% Uppe pper Egyp Egypt Regio ion 18% JORDAN 12.6% 2011 Sudan Alexandria ia Regio ion FY2018 9% Branches Delt lta Regio ion Nigeria 29% Branches SUDAN 1.8% 2011 10 FY2018 branches 23 NIGERIA branches 1.6% 2018 FY2018 5 INTEGRATED DIAGNOSTICS HOLDINGS

Favorable Industry Dynamics Structural Growth Drivers Powerful structural growth drivers underpin Egypt’s healthcare growth story, including an ever -expanding population, rising lifestyle diseases, favorable government regulation and increased medical tourism Lab tests per capita (2012) Hig igh Dise Disease Bur urden 23.2 Ope perating in in a a stil ill un under-penetrated The Egyptian population is marked by a high incidence of mar arket lifestyle-related medical conditions, with obesity being a 10.1 9.6 Healthcare expenditures- notable example given its high correlation with many life- per-capita and lab tests- threatening illnesses including cardiovascular disease, 2.5 per-capita demonstrate diabetes and cancer. the underpenetrated nature of the IDH’s Egypt Oman Saudi Arabia USA markets. Adult Egyptian population that is 35 35% obese Source: Analysis of the US Clinical Laboratory Market; Frost & Sullivan – March 2012 – NHS UK Afr African Pop opulations s Mid iddle Eas astern Pop opulations Large Lar Egyptian children who are 10% 10% 2016 (in millions) 2016 (in millions) Pop opulations considerably overweight 189 89 Approaching 100 million, Egypt is the 96 96 Heart disease, the leading cause of third most populous 80 80 80 80 28% 28% death, highly correlated with country in Africa and by 102 02 obesity far the most populous 96 96 79 79 country in the Middle 37 37 East. 56 56 32 32 28 28 Heightened Health Consciousness A growing consumer class is, however, becoming more Top p 5 African an and d Mi Midd ddle e health and wellness conscious. East aster ern n Coun untry Nigeria Ethiopia Egypt DR Congo Tanzania Egypt Iran Turkey Iraq KSA Yemen Popu pulat ation ons Source: World Bank *CAPMAS (Central Agency for Public Mobilization and Statistics) recently announced that Egypt’s population has reached 104.2 million. 6 INTEGRATED DIAGNOSTICS HOLDINGS

Asset-light Business Model Hub, Spokes and Spikes IDH’s “Hub, Spoke and Spike” business model enables the Company to organically expand its reach in highly-fragmented markets with underserved diagnostic services demand Mega Lab: “Hub” • The Mega Lab, the largest automated lab in Egypt, serves as IDH’s diagnostic “Hub,” equipped with the latest technology to provide a full suite of diagnostic tests. • Significant cost synergies are realized on kits, logistics and quality control. B Labs: “ Spokes ” • The B Labs serve as “Spokes” that reduce traffic to the Mega Lab by processing routine test on site including chemistry, parasitology and hematology. • B Labs are both large in size and higher in capacity than the C Labs. • At 31 December 2018, there were seven B Labs in Egypt and 19 in Jordan. C Labs: “Spikes” • The C Labs are collection centers, conducting the most basic of tests. • Because they require low capital to open, they enable IDH to expand its reach in highly-fragmented markets. • Typical C Labs take 1-2 months to set up and 4-6 months to break even. • At 31 December 2018, there were 396 operational C Labs. 7 INTEGRATED DIAGNOSTICS HOLDINGS

Investment Highlights IDH is an attractive investment opportunity with compelling fundamentals, present in fast-growing, under-served markets Formidable playing field with structural growth drivers, 1 high barriers to entry and a highly fragmented market Established business model with strong brand recognition 2 and market leading position Experienced, entrepreneurial and longstanding management team and 3 adherence to best corporate governance practice 4 Strong unlevered balance sheet and strong cash generation Strong earnings with attractive margins through operational performance, 5 and historical strong organic growth 6 Allo lowin ing g for r capit italiz lizatio ion on on mult multip iple le future re growth avenues 8 INTEGRATED DIAGNOSTICS HOLDINGS

FY2018 Results 9 INTEGRATED DIAGNOSTICS HOLDINGS

Financial Highlights Strong Financial Performance IDH’s performance in 2018 demonstrates our Group’s ability to deliver sustained, double -digit growth with strong margins Revenue Breakup EGP 1,921 mn EGP 948 mn In revenue in FY2018 Gross Profit in FY2018 ▲ 27% y-o-y ▲ 30% y-o-y / 49% margin IDH revenue by geography IDH revenue by type (FY2018) (FY2018) EGP 762 mn EGP 497 mn EBITDA in FY2018 Net Profit in FY2018 ▲ 27% y-o-y / 40% margin ▲ 29% y-o-y / 26% margin 2% 2% 13% Revenue Growth Drivers 41% 59% +29% +27% 250 1,922 1,514 84% 82 173 169 - 15 5 1,171 92 8% 14% 7% 12% 16% -1% Walk-in Corporate Egypt Jordan Sudan Nigeria 10 10 INTEGRATED DIAGNOSTICS HOLDINGS

Financial Highlights Results Driven by Organic Operational Growth FY2018 FY2017 % chan hange Wa Walk-in n Cont ntrac act Total al Wa Walk-in n Cont ntrac act Total al Wa Walk-in n Cont ntrac act Total al Revenue (EGP ‘000) 779,969 1,141,483 1,921,452 591,463 922,794 1,514,257 32% 24% 27% % of Revenu enue 41% 59% 100% 39% 61% 100% Patien ents s ('00 000) 0) 1,97 970 5,07 078 7,04 048 1,68 682 4,68 685 6,36 367 17% 17% 8% 8% 11% 11% 28% 72% 100% 26% 74% 100% % of Patient ents Revenu enue per Patient ent (EGP) P) 396 225 273 352 197 238 13% 14% 15% Test ests s ('000 '000) 6,56 560 22,206 06 28,766 66 5,91 918 19,746 46 25,664 64 11% 11% 12% 12% 12% 12% % of Test sts 23% 77% 100% 23% 77% 100% Revenu enue per Test st (EGP) P) 119 51 67 100 47 59 19% 10% 13% Test est per Patient ent 3.3 4.4 4.1 3.5 4.2 4.0 -5% 4% 1% EGP 273 423 7.0 mn 28.8 mn EGP 67 Avg. revenue per patient in Branches in FY2018 Patients served in FY2018 Tests performed in FY2018 Avg. revenue per test in FY2018 FY2018 ▲ 10% y-o-y ▲ 11% y-o-y ▲ 12% y-o-y ▲ 13% y-o-y ▲ 15% y-o-y 11 11 INTEGRATED DIAGNOSTICS HOLDINGS

Financial Highlights IDH’s Results Build on a Consistent Growth Trajectory in Excess of Market Challenges Number of of Pat Patients Number of of Tests ts Number of of Branch ches Re Revenues EB EBITDA (millions) (millions) (branches) (EGP MN) (EGP MN) 423 7.00 383 762 28.8 6.40 354 1,921 25.7 5.82 5.79 5.58 314 24.0 23.8 602 22.3 288 1,514 511 435 1,171 374 1,015 860 12 12 INTEGRATED DIAGNOSTICS HOLDINGS